Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17;16(6):e0253310.
doi: 10.1371/journal.pone.0253310. eCollection 2021.

Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy

Hyun-Jung Lee  1 , Hyung-Kwan Kim  1 , Bong-Sung Kim  2 , Kyung-Do Han  2 , Jun-Bean Park  1 , Heesun Lee  1 , Seung-Pyo Lee  1 , Yong-Jin Kim  1
Affiliations

Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy

Hyun-Jung Lee et al. PLoS One. .

Abstract

Background: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs.

Methods: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013-2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke.

Results: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65-0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation.

Conclusion: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality.

PubMed Disclaimer

Conflict of interest statement

HKK reports research grants from Actelion, GSK, Bayer Korea, Handok, Dae-Woong, Hanmi, Ildong, JW pharmaceutical, Samjin and Norvatis. The remaining authors declare no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Study inclusion flow.
OAC, oral anticoagulant; AF, atrial fibrillation; VTE, venous thromboembolism; GI, gastrointestinal; PPI, proton pump inhibitor.
Fig 2
Fig 2. Weighted Kaplan-Meier curves for upper gastrointestinal bleeding events according to oral anticoagulants.
NOAC, non-vitamin K antagonist oral anticoagulant.
Fig 3
Fig 3. Differential risk of upper gastrointestinal bleeding, death, and ischemic stroke in users of warfarin and 4 NOACs.
In patients on combined proton pump inhibitor and oral anticoagulant therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no significant difference among the OACs in risk of stroke. *Adjusted for age, sex, atrial fibrillation, venous thromboembolism, comorbidities (hypertension, diabetes mellitus, chronic kidney disease, ischemic heart disease, heart failure, peptic ulcer disease), and concomitant use of aspirin, P2Y12 inhibitor, and nonsteroidal anti-inflammatory drug. †Additionally adjusted for the CHA2DS2-VASc score. NOAC, non-vitamin K antagonist oral anticoagulant; AF, atrial fibrillation.
Fig 4
Fig 4. Comparison of upper gastrointestinal bleeding risk in users of warfarin and 4 NOACs with consideration of dose regimens.
*IR: incidence rate per 1000 person-years. †Adjusted for age, sex, atrial fibrillation, venous thromboembolism, comorbidities (hypertension, diabetes mellitus, chronic kidney disease, ischemic heart disease, heart failure, peptic ulcer disease), and concomitant use of aspirin, P2Y12 inhibitor, and nonsteroidal anti-inflammatory drug. NOAC, non-vitamin K antagonist oral anticoagulant; UGIB, upper gastrointestinal bleeding.
Fig 5
Fig 5. Upper gastrointestinal bleeding risk of NOACs with reference to warfarin in various subgroups.
*IR: incidence rate per 1000 person-years. †Adjusted for age, sex, atrial fibrillation, venous thromboembolism, comorbidities (hypertension, diabetes mellitus, chronic kidney disease, ischemic heart disease, heart failure, peptic ulcer disease), and concomitant use of aspirin, P2Y12 inhibitor, and nonsteroidal anti-inflammatory drug. NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, nonsteroidal anti-inflammatory drug; NVAF, non-valvular atrial fibrillation; UGIB, upper gastrointestinal bleeding; VTE, venous thromboembolism.
See this image and copyright information in PMC

References

    1. Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol. 2017;69(15):1952–67. doi: 10.1016/j.jacc.2017.01.064 - DOI - PubMed
    1. Aronow WS, Banach M. Atrial Fibrillation: The New Epidemic of the Ageing World. J Atr Fibrillation. 2009;1(6):154. doi: 10.4022/jafib.154 - DOI - PMC - PubMed
    1. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–17. doi: 10.1016/j.jacc.2008.08.002 - DOI - PubMed
    1. Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology. 2015;149(3):586–95 e3. doi: 10.1053/j.gastro.2015.05.002 - DOI - PubMed
    1. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA. 2018;320(21):2221–30. doi: 10.1001/jama.2018.17242 - DOI - PMC - PubMed

Publication types

MeSH terms